Details of the Drug Combination

General Information of Drug Combination (ID: DCF1DRL)

Drug Combination Name

Hepzato ER819762

Indication

Disease Entry	Status	REF
Adenocarcinoma	Investigative	[1]

Component Drugs

Hepzato DM2AZPP

ER819762 DMSG91J

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: HCC-2998

Zero Interaction Potency (ZIP) Score: 0.59

Bliss Independence Score: 4.3

Loewe Additivity Score: 3.25

LHighest Single Agent (HSA) Score: 1.51

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[2]

Indication(s) of ER819762

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[3]

ER819762 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Antagonist	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Clear cell renal cell carcinoma	DC3AE0G	A498	Investigative	[5]
Glioma	DCJMUDT	SF-295	Investigative	[5]
Plasma cell myeloma	DC0096A	RPMI-8226	Investigative	[5]
Colon adenocarcinoma	DCSL8O9	COLO 205	Investigative	[6]
Lung adenocarcinoma	DCR87ML	HOP-62	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
4	A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.